FDA approves Roche's Wilserdly for advanced breast cancer
The oral drug is authorized with everolimus for eligible patients with ESR1-mutated advanced or metastatic breast cancer.

Roche secured U.S. Food and Drug Administration approval Monday for its oral breast cancer drug Wilserdly, which the company has previously said could become its top seller ever, STAT reported.
Wilserdly, also called giredestrant, is authorized alongside everolimus. Roche said the treatment is for adults with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer. Eligible patients must have had a recurrence during or after endocrine-based adjuvant therapy, or progression on at least one endocrine-based regimen for metastatic disease.
An ESR1 mutation can signal that a breast tumor is becoming resistant to standard treatments, Roche said. Such mutations develop in up to 40% of patients with hormone receptor-positive metastatic breast cancer.
"Patients with advanced breast cancer progressing on endocrine therapies often face difficult choices and deteriorating quality of life as options narrow," Dr. Erica L. Mayer, director of breast cancer clinical research at the Dana-Farber Cancer Institute, said in Roche's announcement.
The FDA also authorized a blood test to find patients eligible for treatment. The recommended giredestrant dose is 30 milligrams once a day.
Trial results
Roche said Wilserdly with everolimus reduced the risk of progression or death by 62% in patients with ESR1-mutated tumors in the phase III evERA trial, compared with standard endocrine therapy and everolimus. The company said participants' cancers were progressing after prior CDK4/6 inhibitor therapy, and the results appeared in The New England Journal of Medicine.
The stratified hazard ratio was 0.38.
The late-stage study supporting approval included 207 patients with ESR1-mutated tumors, Reuters reported. The Wilserdly combination delayed progression for a median of 10 months, compared with 5.5 months for another hormone treatment with everolimus, Reuters reported.
Roche said giredestrant is an oral selective estrogen receptor degrader, or SERD. It is designed to prevent estrogen from binding to its receptor, prompting the receptor protein to break down and stopping or slowing cancer cell growth.
Both drugs are taken orally, with no injections needed, Roche said. In the announcement, Roche chief medical officer Levi Garraway said the regimen "allows advanced breast cancer patients to take their treatment from home."
The price and timing of patient access were not immediately known.
Roche seeks wider approval
STAT reported that the decision was among the most important Roche had been awaiting from regulators. Based in Basel, Switzerland, Roche has a long breast cancer history through Herceptin, sold by subsidiary Genentech, but has fallen behind oncology rivals in recent years, STAT said.
Roche has applied to expand Wilserdly's use. Its New Drug Application seeks adjuvant treatment for adults with ER-positive, HER2-negative, stage I, II and III breast cancer who face an intermediate to high risk of recurrence. The application draws on the phase III lidERA study and was accepted under Priority Review.
Roche said approval for that use would make Wilserdly the first new adjuvant endocrine therapy in more than 20 years. The company sponsors six phase III trials in Wilserdly's development program, with further filings underway outside the United States.
"We remain focused on maximising the clinical impact of Wilserdly across the continuum of care, including early-stage disease," Teresa Graham, CEO of Roche Pharmaceuticals, said in the announcement.
The FDA's decision date for the early-stage application is Nov. 30.
Sources
- STAT: FDA approves new breast cancer drug, providing new option for some patients, boost for Roche
- roche.com: FDA approves Roche’s Wilserdly (giredestrant), a next-generation oral SERD, for ER-positive, ESR1-mutated advanced breast cancer
- Yahoo News: US FDA approves Roche's oral treatment for advanced breast cancer






